UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1173-12
Program Prior Authorization/Notification
Medication Ninlaro® (ixazomib)
P&T Approval Date 1/2016, 4/2016, 3/2017, 3/2018, 3/2019, 3/2020, 3/2021, 3/2022,
3/2023, 3/2024, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Ninlaro (ixazomib) is a proteasome inhibitor indicated in combination with lenalidomide and
dexamethasone for the treatment of patients with multiple myeloma who have received at least
one prior therapy.
Limitations of Use:
Ninlaro is not recommended for use in the maintenance setting or in newly diagnosed multiple
myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical
trials.
The National Comprehensive Cancer Network (NCCN) also recommends use of Ninlaro as
primary or maintenance therapy for multiple myeloma, for treatment of relapsed or refractory
systemic light chain amyloidosis, and for treatment of Waldenström
macroglobulinemia/lymphoplasmacytic lymphoma in combination with rituximab and
dexamethasone.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Ninlaro will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Multiple Myeloma
1. Initial Authorization
© 2025 UnitedHealthcare Services, Inc.
1
a. Ninlaro will be approved based on the following criterion:
(1) Diagnosis of multiple myeloma
Authorization will be issued for 12 months.
2. Reauthorization
a. Ninlaro will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Ninlaro therapy
Authorization will be issued for 12 months.
C. Systemic Light Chain Amyloidosis
1. Initial authorization
a. Ninlaro will be approved based on the following criterion:
(1) Diagnosis of relapsed or refractory systemic light chain amyloidosis
Authorization will be issued for 12 months.
2. Reauthorization
a. Ninlaro will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Ninlaro therapy
Authorization will be issued for 12 months.
D. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
1. Initial authorization
a. Ninlaro will be approved based on both of the following criteria:
(1) Diagnosis of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
-AND-
(2) Used in combination with Rituxan (rituximab) and dexamethasone
Authorization will be issued for 12 months.
2. Reauthorization
a. Ninlaro will be approved based on the following criterion:
© 2025 UnitedHealthcare Services, Inc.
2
(1) Patient does not show evidence of progressive disease while on Ninlaro therapy
Authorization will be issued for 12 months.
E. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category
of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Ninlaro [package insert]. Cambridge, MA: Takeda Pharmaceutical Company Ltd.; July 2024
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org. Accessed May 2, 2025.
Program Prior Authorization/Notification – Ninlaro (ixazomib)
Change Control
1/2016 New program.
4/2016 Removed Revlimid & dexamethasone requirement from coverage criteria
per NCCN. Updated background and references.
3/2017 Annual Review. Updated background information and criteria to include
NCCN recommendation for primary use in combination with Revlimid
and dexamethasone.
3/2018 Annual review with no changes to coverage criteria. Updated reference.
3/2019 Annual review. Updated background information and criteria to include
NCCN recommendation for relapsed/refractory systemic light chain
amyloidosis. Updated criteria for multiple myeloma as Ninlaro is no
longer recommended alone for relapsed or progressive disease. Updated
reference.
3/2020 Annual review. Updated background information and criteria to include
NCCN recommendation for transplant candidates, and Waldenström
© 2025 UnitedHealthcare Services, Inc.
3
Macroglobulinemia/Lymphoplasmacytic Lymphoma. Added standard
language for NCCN recommended regimens. Updated reference.
3/2021 Annual review. Updated references.
3/2022 Annual review. Updated references.
3/2023 Annual review with no change to coverage criteria. Updated background
and references. Added state mandate footnote.
3/2024 Annual review. Updated background and coverage criteria per NCCN
guidelines. Updated references.
6/2024 Updated Multiple Myeloma criteria to only diagnosis.
6/2025 Annual review with no change to coverage criteria. Updated background
and reference.
© 2025 UnitedHealthcare Services, Inc.
4